Skip to main
PTGX

Protagonist Therapeutics (PTGX) Stock Forecast & Price Target

Protagonist Therapeutics (PTGX) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 50%
Buy 43%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Protagonist Therapeutics is primed for success with its strong pipeline and strategic collaborations, such as the recent $200M opt-out fee from Takeda and potential milestone payments from its partners. With a strong cash balance of $620M and a projected runway into at least 2028, the company is well-positioned to continue developing its lead candidate, rusfertide, for polycythemia vera, while also exploring other promising programs in its pipeline. Furthermore, Protagonist's success with its partnered programs, such as Icotyde's projected peak sales of over $10B, highlights the potential for the company's proprietary technology platform and positions it for continued stock outperformance.

Bears say

Protagonist Therapeutics is facing potential dilution in their shares, which is reflected in their recent 10-Q filing. Despite this, their potential approval for rusfertide in polycythemia vera and partnerships in their pipeline may lead to short-term profitability. However, with no current products on the market and uncertainty in pipeline development, their long-term financial stability remains questionable.

Protagonist Therapeutics (PTGX) has been analyzed by 14 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 43% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Protagonist Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Protagonist Therapeutics (PTGX) Forecast

Analysts have given Protagonist Therapeutics (PTGX) a Buy based on their latest research and market trends.

According to 14 analysts, Protagonist Therapeutics (PTGX) has a Buy consensus rating as of May 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $109.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $109.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Protagonist Therapeutics (PTGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.